Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Very Early Detection of Response to Imatinib Mesylate Therapy of Gastrointestinal Stromal Tumours Using 18Fluoro-Deoxyglucose-Positron Emission Tomography

T. HEINICKE, E. WARDELMANN, T. SAUERBRUCH, H.J. TSCHAMPA, A. GLASMACHER and H. PALMEDO
Anticancer Research November 2005, 25 (6C) 4591-4594;
T. HEINICKE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thomas.heinicke{at}ukb.uni-bonn.de
E. WARDELMANN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. SAUERBRUCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.J. TSCHAMPA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. GLASMACHER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. PALMEDO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 25 no. 6C 4591-4594
PMID 
16334147

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received March 17, 2005
  • Accepted June 17, 2005
  • Published online November 1, 2005.

Copyright & Usage 
Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. T. HEINICKE1,
  2. E. WARDELMANN2,
  3. T. SAUERBRUCH1,
  4. H.J. TSCHAMPA3,
  5. A. GLASMACHER1 and
  6. H. PALMEDO4
  1. 1Department of Internal Medicine I, University of Bonn, Bonn, Germany
  2. 2Department of Pathology, University of Bonn, Bonn, Germany
  3. 3Department of Radiology, University of Bonn, Bonn, Germany
  4. 4Department of Nuclear Medicine, University of Bonn, Bonn, Germany
  1. Correspondence to: Thomas Heinicke, MD, Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany. Tel: +49 (0)228 287 5507, Fax: +49 (0) 228 287 4323, e-mail: thomas.heinicke{at}ukb.uni-bonn.de

Statistics from Altmetric.com

Cited By...

  • 47 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 25, Issue 6C
1 Nov 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Very Early Detection of Response to Imatinib Mesylate Therapy of Gastrointestinal Stromal Tumours Using 18Fluoro-Deoxyglucose-Positron Emission Tomography
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Very Early Detection of Response to Imatinib Mesylate Therapy of Gastrointestinal Stromal Tumours Using 18Fluoro-Deoxyglucose-Positron Emission Tomography
T. HEINICKE, E. WARDELMANN, T. SAUERBRUCH, H.J. TSCHAMPA, A. GLASMACHER, H. PALMEDO
Anticancer Research Nov 2005, 25 (6C) 4591-4594;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Very Early Detection of Response to Imatinib Mesylate Therapy of Gastrointestinal Stromal Tumours Using 18Fluoro-Deoxyglucose-Positron Emission Tomography
T. HEINICKE, E. WARDELMANN, T. SAUERBRUCH, H.J. TSCHAMPA, A. GLASMACHER, H. PALMEDO
Anticancer Research Nov 2005, 25 (6C) 4591-4594;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
  • Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response
  • The Value of Establishing the Quantitative Accuracy of PET/CT Imaging
  • Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
  • ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with 18F-FDG PET and Correlation with Genotype and GLUT4 Expression
  • [18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
  • Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
  • Disease Progression Following Imatinib Failure in Gastrointestinal Stromal Tumors: Role of Surgical Therapy
  • Google Scholar

More in this TOC Section

  • Comparison of RATS Lobectomy and VATS Lobectomy for Early-stage Non-small Cell Lung Cancer
  • Effectiveness of Chemotherapy With/Without Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Population-based Target Trial Emulation Study
  • Genomic Profiling of Cancerous Areas, Dysplasia, and Background Mucosa in Ulcerative Colitis-associated Colorectal Cancer
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire